As part of our mission to deliver the latest medical breakthroughs, CSSIFM physicians conduct clinical trials that test new treatments for a wide range of patients and cancer types. The following trials are being conducted at CSSIFM and new ones are on the horizon. Please fill out the Clinical Trial Inquiry to get more information.
Clinical Trial Inquiry
Open-label, Randomized, Comparative Phase 2 Study of Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for First and Second Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer
https://clinicaltrials.gov/ct2/show/NCT04390399
Indication: Pancreatic Cancer
NCT04390399 | Quilt-88
Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of Prophylactic
Vaccination with 2nd Generation E1/E2B/E3-Deleted Adenoviral-COVID-19 in Normal Healthy
Volunteers
https://clinicaltrials.gov/ct2/show/NCT04591717
NCT04591717 | QUILT-COVID-19-hAd5-Vaccine (QUILT-4.001)
Orally Administered Prophylactic Vaccination With 2nd Generation (E1/E2B/E3-Deleted) Adenoviral
COVID-19 in Normal Healthy Volunteers
https://clinicaltrials.gov/ct2/show/NCT04732468
NCT04732468 | COVID-4.005
Costa Mesa
El Segundo
As part of our mission to deliver the latest medical breakthroughs, CSSIFM physicians conduct clinical trials that test new treatments for a wide range of patients and cancer types. The following trials are being conducted at CSSIFM and new ones are on the horizon. Please fill out the Clinical Trial Inquiry to get more information.
Clinical Trial Inquiry
Open-label, Randomized, Comparative Phase 2 Study of Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for First and Second Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer
https://clinicaltrials.gov/ct2/show/NCT04390399
Indication: Pancreatic Cancer
NCT04390399 | Quilt-88
Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of Prophylactic
Vaccination with 2nd Generation E1/E2B/E3-Deleted Adenoviral-COVID-19 in Normal Healthy
Volunteers
https://clinicaltrials.gov/ct2/show/NCT04591717
NCT04591717 | QUILT-COVID-19-hAd5-Vaccine (QUILT-4.001)
Orally Administered Prophylactic Vaccination With 2nd Generation (E1/E2B/E3-Deleted) Adenoviral
COVID-19 in Normal Healthy Volunteers
https://clinicaltrials.gov/ct2/show/NCT04732468
NCT04732468 | COVID-4.005